Dimensional Fund Advisors LP Purchases 411,628 Shares of Boston Scientific Co. (NYSE:BSX)

Dimensional Fund Advisors LP boosted its position in Boston Scientific Co. (NYSE:BSX) by 8.9% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 5,047,661 shares of the medical equipment provider’s stock after buying an additional 411,628 shares during the quarter. Dimensional Fund Advisors LP’s holdings in Boston Scientific were worth $388,724,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of the company. Sierra Summit Advisors LLC bought a new position in shares of Boston Scientific in the fourth quarter worth about $8,038,000. TD Asset Management Inc increased its position in Boston Scientific by 10.7% in the 4th quarter. TD Asset Management Inc now owns 1,615,932 shares of the medical equipment provider’s stock worth $93,417,000 after buying an additional 155,565 shares during the period. BI Asset Management Fondsmaeglerselskab A S lifted its holdings in shares of Boston Scientific by 225.6% during the first quarter. BI Asset Management Fondsmaeglerselskab A S now owns 105,671 shares of the medical equipment provider’s stock worth $7,237,000 after buying an additional 73,219 shares during the last quarter. BDF Gestion acquired a new position in shares of Boston Scientific during the second quarter worth approximately $3,570,000. Finally, Precision Wealth Strategies LLC bought a new stake in shares of Boston Scientific in the fourth quarter valued at approximately $956,000. Institutional investors own 89.07% of the company’s stock.

Insider Buying and Selling at Boston Scientific

In other news, EVP Wendy Carruthers sold 6,983 shares of the firm’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $74.12, for a total value of $517,579.96. Following the completion of the sale, the executive vice president now directly owns 40,188 shares in the company, valued at $2,978,734.56. The sale was disclosed in a filing with the SEC, which is accessible through this link. In the last quarter, insiders sold 20,949 shares of company stock worth $1,627,877. 0.50% of the stock is currently owned by insiders.

Boston Scientific Trading Up 0.2 %

Shares of BSX stock opened at $83.51 on Tuesday. The company has a market capitalization of $122.52 billion, a P/E ratio of 70.18, a P/E/G ratio of 2.75 and a beta of 0.79. Boston Scientific Co. has a 12-month low of $48.35 and a 12-month high of $84.11. The company has a quick ratio of 1.14, a current ratio of 1.61 and a debt-to-equity ratio of 0.44. The firm has a 50-day moving average price of $78.23 and a 200 day moving average price of $74.28.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, July 24th. The medical equipment provider reported $0.62 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.58 by $0.04. The company had revenue of $4.12 billion during the quarter, compared to analysts’ expectations of $4.02 billion. Boston Scientific had a net margin of 12.00% and a return on equity of 16.59%. Boston Scientific’s quarterly revenue was up 14.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.53 earnings per share. Research analysts forecast that Boston Scientific Co. will post 2.4 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on BSX. Raymond James boosted their target price on shares of Boston Scientific from $91.00 to $94.00 and gave the stock a “strong-buy” rating in a research report on Wednesday, September 4th. Canaccord Genuity Group boosted their price objective on shares of Boston Scientific from $83.00 to $88.00 and gave the stock a “buy” rating in a report on Thursday, July 25th. Needham & Company LLC increased their target price on shares of Boston Scientific from $82.00 to $86.00 and gave the company a “buy” rating in a research note on Thursday, July 25th. Royal Bank of Canada restated an “outperform” rating and set a $85.00 price target on shares of Boston Scientific in a research note on Thursday, July 25th. Finally, The Goldman Sachs Group began coverage on Boston Scientific in a report on Thursday, May 30th. They issued a “buy” rating and a $90.00 price target for the company. Three equities research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Boston Scientific presently has a consensus rating of “Moderate Buy” and a consensus price target of $85.38.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.